Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:33:48.223Z.
Calculation as of: 2026-10-06T16:33:48.223Z.
Quote observation: 2026-10-06T16:27:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f827d960650d67e3900ac6098f04a5e2078fd3b8121965df68c70cd2fd602cdf
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$218.36M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.39M
EV/EBIT Ratio
17.41x
TTM Avg
25.81x
3Y Avg
146.27x
5Y Avg
146.27x
Market Cap
$214.35M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$208.90M
EV/EBIT Ratio
N/A
TTM Avg
6.44x
3Y Avg
6.44x
5Y Avg
6.44x
Market Cap
$221.27M
EV/EBIT Ratio
N/A
TTM Avg
1.44x
3Y Avg
1.44x
5Y Avg
1.44x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $218.36M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.39M | 17.41x | 25.81x | 146.27x | 146.27x |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.35M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $217.34M | N/A | 19.40x | 19.40x | 19.40x |
| Lyell Immunopharma, Inc. (LYEL)vs › | $218.09M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $211.80M | 6.75x | 6.24x | 9.86x | 9.86x |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $208.90M | N/A | 6.44x | 6.44x | 6.44x |
| Sionna Therapeutics, Inc. (SION)vs › | $209.27M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $221.27M | N/A | 1.44x | 1.44x | 1.44x |
| Pro-Dex, Inc. (PDEX)vs › | $206.63M | 16.67x | 15.79x | 14.74x | 15.50x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
